Results
919
Companies with promising cash flow potential yet trading below their fair value, as determined by SWS DCF valuation, signaling opportunity for value-oriented investors.
919 companies
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
4165 | JP¥1,597.00 | 20.5% | 140.9% | JP¥64.7b | JP¥740.00 | PE201.6x | E64.1% | n/a | Software | ||
CCC | SEK 17.55 | 5.7% | 26.3% | SEK 1.9b | n/a | PE35.7x | E28.5% | 0% | Capital Goods | ||
SES | €75.10 | -1.2% | -30.1% | €1.2b | €153.13 | PE14.9x | E13.8% | 1.3% | Tech | ||
A326030 | ₩95,400.00 | -7.6% | 9.9% | ₩7.5t | ₩120,800.00 | PE130.2x | E49.7% | n/a | Pharmaceuticals & Biotech | ||
6928 | JP¥1,473.00 | -2.3% | -4.9% | JP¥9.6b | JP¥2,000.00 | PE31.7x | E46.5% | 4.8% | Tech | ||
IMH | ฿4.96 | -0.4% | -37.6% | ฿1.1b | n/a | PS1.3x | E123.0% | 2.8% | Healthcare | ||
SNAP | US$11.42 | 7.7% | -8.8% | US$19.2b | US$13.04 | PS3.7x | E64.2% | n/a | Media | ||
688389 | CN¥15.53 | -5.8% | -34.9% | CN¥6.7b | CN¥22.45 | PE17.5x | E20.5% | 1.8% | Healthcare | ||
WKS | S$0.27 | -5.3% | 31.7% | S$118.9m | S$0.37 | PE61.8x | E35.7% | 1.9% | Media | ||
2471 | JP¥340.00 | -1.2% | -15.2% | JP¥26.9b | JP¥450.00 | PE19.3x | E21.5% | 2.9% | Commercial Services | ||
CLNX | €32.54 | 2.6% | -4.9% | €23.0b | €44.03 | PS5.7x | E73.2% | 0.2% | Telecom | ||
2492 | JP¥288.00 | -0.3% | -40.0% | JP¥65.2b | JP¥410.00 | PE142.7x | E40.9% | 0.5% | Commercial Services | ||
PINS | US$30.02 | 6.3% | -5.2% | US$20.3b | US$40.07 | PE94x | E34.4% | n/a | Media | ||
AIM | AU$0.70 | -14.0% | 151.8% | AU$147.2m | AU$0.70 | PS2.2x | E77.0% | n/a | Commercial Services | ||
1818 | HK$11.70 | 3.2% | 22.8% | HK$39.8b | HK$16.15 | PE30.8x | E34.7% | 0.4% | Materials | ||
NBTB | US$50.45 | 2.4% | 39.9% | US$2.4b | US$51.33 | PB1.6x | E21.6% | 2.7% | Banks | ||
688266 | CN¥64.04 | -1.8% | 36.8% | CN¥17.0b | CN¥79.00 | PS34.7x | E125.6% | n/a | Pharmaceuticals & Biotech | ||
DE | CA$6.18 | 1.8% | -20.9% | CA$121.4m | CA$7.44 | PE47.3x | E55.1% | 8.7% | Capital Goods | ||
TBCG | UK£31.95 | 0.2% | 16.0% | UK£1.8b | UK£40.07 | PB1.2x | E16.8% | 6.3% | Banks | ||
688046 | CN¥12.94 | -3.6% | -32.6% | CN¥5.3b | CN¥16.75 | PE37.9x | E27.9% | 0.5% | Pharmaceuticals & Biotech | ||
1501 | HK$27.50 | -3.2% | -1.8% | HK$4.8b | HK$35.04 | PE26.9x | E27.2% | 1.1% | Healthcare | ||
4385 | JP¥2,097.50 | 9.0% | -29.7% | JP¥344.2b | JP¥2,725.42 | PE25.3x | E16.4% | n/a | Retail | ||
SABK | US$15.35 | -12.0% | 51.4% | US$115.5m | US$17.50 | PB1x | E24.8% | 0.7% | Banks | ||
FF | €7.94 | -2.7% | 0.6% | €194.4m | €12.00 | PE40.1x | E30.7% | 1.5% | Pharmaceuticals & Biotech |